Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia

Cell Cycle

Volumn 10, Issue 18, 2011, Pages 3168-3175

  Boehrer, Simone ^a,b   Galluzzi, Lorenzo ^a,c,d   Lainey, Elodie ^a,e   Bouteloup, Cyrielle ^a,c,d   Tailler, Maximilien ^a,c,d   Harper, Francis ^f   Pierron, Gérard ^f   Adès, Lionel ^a,b   Thépot, Sylvain ^a,b   Sébert, Marie ^a,b   Gardin, Claude ^b   De Botton, Stéphane ^d   Fenaux, Pierre ^a,b   Kroemer, Guido ^a,d,g,h,i  

^a INSERM   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f CNRS   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Apoptosis; BAY 61 3606; Cancer; KG 1; LYN; Piceatannol

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTILEUKEMIC AGENT; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN; PICEATANNOL; PROTEIN TYROSINE KINASE; RAPAMYCIN; S6 KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGOSOME; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MYELODYSPLASTIC SYNDROME;

MAMMALIA;

EID: 80052906831     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.18.16599     Document Type: Article

References (35)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730-7; PMID:9212098; DOI:10.1038/nm0797-730.
2. Passegué E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 2003; 100:11842-9; PMID:14504387; DOI:10.1073/pnas.2034201100.
3. Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 2002; 3:179-98; PMID:12194988; DOI:10.1146/annurev.genom.3.032802. 115046.
4. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008; 22:240-8; PMID:18200041; DOI:10.1038/sj.leu.2405078.
5. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20:1943-9; PMID:16990778; DOI:10.1038/sj.leu.2404381.
6. Dos Santos C, Demur C, Bardet V, Prade-Houdellier N, Payrastre B, Recher C. A critical role for Lyn in acute myeloid leukemia. Blood 2008; 111:2269-79; PMID:18056483; DOI:10.1182/blood-2007-04-082099.
7. Cepero V, Sierra JR, Giordano S. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis. Curr Pharm Des 2010; 16:1396-409; PMID:20166985; DOI:10.2174/138161210791033905.
8. Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; DOI:10.1182/blood- 2007-07-100362.
9. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer. Blood 2007; 110:1079-80; PMID:17644748; DOI:10.1182/blood-2007-01-069856.
10. Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 2009; 16:281-94; PMID:19800574; DOI:10.1016/j.ccr.2009.08.018.
11. Lindhagen E, Eriksson A, Wickstrom M, Danielsson K, Grundmark B, Henriksson R, et al. Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia. Eur J Haematol 2008; 81:344-53; PMID:18637032.
12. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J Clin Oncol 2008; 26:3645-6; PMID:18640945; DOI:10.1200/JCO.2008.17.0357.
13. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 2005; 106:2841-8; PMID:15998836; DOI:10.1182/blood-2005-02-0488.
14. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009; 6:587-95; PMID:19787002; DOI:10.1038/nrclinonc.2009. 129.
15. Galluzzi L, Kepp O, Kroemer G. Tp53 and MTOR crosstalk to regulate cellular senescence. Aging (Albany NY) 2010; 2:535-7; PMID:20876940.
16. Korotchkina LG, Leontieva OV, Bukreeva EI, Demidenko ZN, Gudkov AV, Blagosklonny MV. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) 2010; 2:344-52; PMID:20606252.
17. Ferrandiz N, Martin-Perez J, Blanco R, Donertas D, Weber A, Eilers M, et al. HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53. DNA Repair (Amst) 2009; 8:390-9; PMID:19150257; DOI:10.1016/j.dnarep.2008. 12.001.
18. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007; 8:931-7; PMID:17712358; DOI:10.1038/nrm2245.
19. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007; 8:741-52; PMID:17717517; DOI:10.1038/nrm2239.
20. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010; 40:280-93; PMID:20965422; DOI:10.1016/j.molcel.2010.09. 023.
21. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4:151-75; PMID:18188003.
22. Tasdemir E, Galluzzi L, Maiuri MC, Criollo A, Vitale I, Hangen E, et al. Methods for assessing autophagy and autophagic cell death. Methods Mol Biol 2008; 445:29-76; PMID:18425442; DOI:10.1007/978-1-59745-157-4-3.
23. Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527-34; PMID:15550488; DOI:10.1182/blood-2004-06-2494.
24. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol-3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1:89-103; PMID:20671809.
25. Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget 2011; 2:222-33; PMID:21447859.
26. Abrams SL, Steelman LS, Shelton JG, Chappell W, Basecke J, Stivala F, et al. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle 2010; 9:1839-46; PMID:20436269; DOI:10.4161/cc.9.9.11544.
27. Puissant A, Robert G, Auberger P. Targeting autophagy to fight hematopoietic malignancies. Cell Cycle 2010; 9:3470-8; PMID:20703092; DOI:10.4161/cc.9.17.13048.
28. Castedo M, Ferri K, Roumier T, Metivier D, Zamzami N, Kroemer G. Quantitation of mitochondrial alterations associated with apoptosis. J Immunol Methods 2002; 265:39-47; PMID:12072177; DOI:10.1016/S0022-1759(02)00069-8.
29. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 2009; 16:1093-107; PMID:19373242; DOI:10.1038/cdd.2009.44.
30. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007; 12:803-13; PMID:17294081; DOI:10.1007/s10495-007- 0720-1.
31. Métivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, et al. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion- specific fluorochromes. Immunol Lett 1998; 61:157-63; PMID:9657269; DOI:10.1016/S0165-2478(98)00013-3.
32. Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, et al. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-8; PMID:18593931; DOI:10.1158/0008-5472.CAN-08-0237.
33. Vicencio JM, Ortiz C, Criollo A, Jones AW, Kepp O, Galluzzi L, et al. The inositol-1,4,5-trisphosphate receptor regulates autophagy through its interaction with Beclin 1. Cell Death Differ 2009; 16:1006-17; PMID:19325567; DOI:10.1038/cdd.2009.34.
34. Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, Senovilla L, et al. Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS ONE 2007; 2:1337; PMID:18159231; DOI:10.1371/journal.pone.0001337.
35. Vitale I, Senovilla L, Jemaa M, Michaud M, Galluzzi L, Kepp O, et al. Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos. EMBO J 2010; 29:1272-84; PMID:20186124; DOI:10.1038/emboj.2010.11.